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Abstract
Diversity within the innate and adaptive immune response to hepatitis C is important
in determining spontaneous resolution (SR) and treatment response. The aim of this
study was to analyze how these variables interact in combination; furthering our
understanding of the mechanisms that drive successful immunological clearance.
Multivariate analysis was performed on retrospectively collected data for 357 patients
previously genotyped for interferon (IFN)-λ3/4, killer cell immunoglobulin (KIR),
human leukocyte antigen (HLA) class I and II and tapasin. High resolution KIR
genotyping was performed for individuals with chronic infection and haplotypes
determined. Outcomes for SR, IFN response and cirrhosis were examined. Statistical
analysis included univariate methods, χ2 test for trend, multivariate logistic regression,
synergy and principal component analysis (PCA). Although KIR2DL3:HLA-C1C1
(P= 0.027), IFN-λ3/4 rs12979860 CC (P= 0.027), tapasin G in individuals with aspar-
tate at residue 114 of HLA-B (TapG:HLA-B114D) (P= 0.007) and HLA-DRB1*04:01
(P= 0.014) were associated with SR with a strong additive influence (χ2 test for trend
P< 0.0001); favorable polymorphisms did not interact synergistically, nor did patients
cluster by outcome. In the treatment cohort, IFN-λ3/4 rs12979860 CC was protective
in hepatitis C virus (HCV) G1 infection and KIR2DL3:HLA-C1 in HCV G2/3. In
common with SR, variables did not interact synergistically. Polymorphisms predictive
of viral clearance did not predict disease progression. In summary, different individuals
resolve HCV infection using discrete and non-interacting immunological pathways.
These pathways are influenced by viral genotype. This work provides novel insights
into the complexity of the interaction between host and viral factors in determining the
outcome of HCV infection.
Introduction
Only 20% of individuals exposed to hepatitis C virus (HCV)
achieve spontaneous resolution (SR) and despite the recent rev-
olution in new drug therapies, HCV remains a common cause
of cirrhosis and liver cancer worldwide with no effective vac-
cine in immediate sight (1, 2). Genetic and functional studies
have identified key molecules and processes involved in clear-
ing HCV spontaneously and using interferon (IFN)-α based
therapies (3–9). These studies have implicated both innate and
adaptive mechanisms in clearing HCV infection.
One of the most impressive findings from Gene Wide Asso-
ciation Studies (GWAS) to date has been the identification
of single nuclear polymorphisms (SNPs) upstream of IFN-λ3
which are protective against HCV chronicity and treatment
failure (3–7). This has been fine mapped to the TT/-G poly-
morphism at rs67272382 in a CpG island, which is in strong
linkage disequilibrium with IFN-λ3 and is most likely to be
the causal variant, with the possibility of defining a new type
3 IFN, IFN-λ4 (10, 11). Whilst this polymorphism has shown
remarkable consistency in its ability to predict spontaneous
and treatment-induced viral clearance across populations, its
protection does not extend to ‘exposed uninfected’ individuals,
suggesting that multiple pathways to clearance may coexist
within a population (12, 13).
The killer cell immunoglobulin (KIR) and human leuko-
cyte antigen (HLA) combinations are also important for
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HCV outcomes in spontaneously resolving infection,
IFN-treatment-associated resolution and in European-exposed
seronegative individuals (8, 14). In these studies, the combina-
tion of KIR2DL3 and its HLA-C group 1 ligands (HLA-C1)
was protective in all groups tested in our UK population. These
findings have been confirmed in sub-groups in other popula-
tions, but it is clear that there is population diversity in how the
KIR gene family contributes to the resolution of HCV infection
(15). The influence of KIR diversity remains important in the
era of triple therapy, until directly acting anti-viral therapies
become cost effective (16, 17).
Within our Caucasian population we recently identified that
an SNP in tapasin, a protein involved in the major histocom-
patibility complex (MHC) class I peptide loading pathway was
associated with resolution of HCV infection (9). The favor-
able tapasin G gene was most protective in individuals carrying
HLA-B alleles with an aspartate at residue 114 of the HLA-B
heavy chain (TapG:HLA-B114D). Individuals with a protective
allele had a stronger T-cell response. Thus, both the adaptive
and innate immune systems are protective against chronic HCV
infection in our UK population. This is borne out by other stud-
ies indicating a role for HLA-class II polymorphisms in the
outcome of HCV infection in the UK (18, 19).
Recent work has studied how the innate immune path-
ways of KIR, HLA-C and IFN-λ3/4 interact. In these studies
it has been shown that for the SNPs associated with worse
outcomes, KIR2DS3, HLA-C2C2 and IFN-λ3/4 (rs8099917
G allele and rs12979860 T allele), there appeared to be an
interaction, as individuals with two susceptibility factors had
significantly worse outcomes than those with only one (20,
21). Conversely no predictive benefit was found on combining
the favorable IFN-λ3/4 polymorphismwith KIR2DL3:HLA-C1
homozygosity for protection against viremia in seronegative
exposed groups (12). On examination of the interaction of class
I and II HLA alleles with KIR and IFN-λ3/4 in the homogenous
Irish HCV cohort and more heterogenous Swiss cohort, nothing
further than an additive effect was seen (22).
Viral genotype is emerging as a central determinant of
whether the above polymorphisms can exert any influence on
viral clearance; for example variants of IFN-λ3/4 play a limited
role in predicting HCV related outcomes in patients infected
with HCV G2/3 (23). Recent work has suggested this may
be a result of genotype 1 viral infection inducing transcripts
which are heavily regulated by IFN-λ3/4, whereas HCV G2/3
infection leads to the upregulation of genes induced by IFN-γ
(24). There was no influence of IFN-λ3/4 polymorphisms on
the transcriptional profile of patients infected with HCV G3
(24). Viral genotype specific host-pathogen interactions are
therefore vital to consider when studying the impact of host
immunogenetics in HCV.
Thus clearance of hepatitis C depends on both innate and
adaptive immune systems implicated in both genetic and cel-
lular studies. However it has been difficult to study how these
systems interact. To do this we have studied our UK HCV
Caucasian population, which has been extensively typed for
polymorphic gene families KIR, HLA-I, HLA-II and IFN-λ3/4.
Materials and methods
A total of 357 patients were included in the study recruited
from two large UK teaching hospitals, University Hospitals
Southampton NHS Foundation Trust and Cambridge Univer-
sity Hospitals NHS Foundation Trust between 2003 and 2007
with ethical approval. Patients were recruited from hepatology
clinics having tested positive for HCV IgG by second gener-
ation enzyme-linked immunosorbent assay (ELISA). Viremia
was confirmed using the HCV Cobas Amplification system
(Roche). SRwas defined as the absence of HCVRNA, 6months
following a positive antibody test. HCV genotyping was per-
formed using quantitative polymerase chain reaction (PCR)
(iQur, Southampton, UK) (9, 12, 14).
DNA was isolated as previously described. Genotyping had
previously been performed for KIR, IFN-λ3/4 rs12979860,
HLA and tapasin (9, 12, 14). Additional high resolution KIR
genotyping was later performed on the patients with chronic
HCV infection to accurately determine KIR copy number and
impute KIR haplotype (25). Demographic data and primary end
points [spontaneous and treatment-induced viral clearance, the
development of cirrhosis and hepatocellular carcinoma (HCC)]
were collected retrospectively by the researchers using the
patient’s electronic medical records.
Statistical analysis of the numeric variables was performed
using descriptive statistics [mean, standard deviation, 95% con-
fidence intervals (CI)] while that for the categorical variables
(frequency, percent) was performed using frequency distribu-
tion and cross-tabulation methods, as appropriate. Univariate
and multivariate analyses were further performed to determine
factor selection and test independence. The multivariate logis-
tic regression was applied using the backward stepwise proce-
dure for all variables that were significant at univariate analy-
sis. The relationships were estimated using the odds ratio (OR)
and its 95% CI. Chi-squared test for trend and Fischer’s exact
test were also used to analyze the benefit of having more than
two protective variables. The interaction between susceptibil-
ity or protective factors was reported using both the synergy
factor (SF), as described by Cortina-Borja et al. (26) and the
synergy index (SI) (27). A P< 0.05 was considered to be sta-
tistically significant, unless stated otherwise. Routine statistical
software packages were used for the analyses (SPSS version 21,
GraphPad Prism). Three-dimensional PCA (rgl package in R)
was used to cluster patients on the basis of their SNP profiles
(28, 29).
Results
Spontaneous resolution
We had previously typed our HCV population for SNPs affect-
ing both innate and adaptive pathways that are associated with
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Table 1 Spontaneous resolution (individual polymorphisms)
Multivariate logistic regression
Genetic factor Genotype Resolved n=61 Chronic n=296 P-value OR (95% CI)
IFN-λ3/4 rs12979860 CC 34 116 0.013 2.55 (1.22–5.31)
KIR:HLA 2DL3:HLA-C1C1 24 70 0.006 3.05 (1.38–6.74)
2DS3 7 71 0.114 0.45 (0.17–1.21)
2DS5 11 87 0.027 0.37 (0.16–0.90)
HLA-DRB1*04:01 14 12 0.011 3.70 (1.36–10.08)
Tapasin & HLA TapG:HLA-B114D 48 148 0.008 3.22 (1.36–7.65)
CI, conﬁdence intervals; HLA, human leukocyte antigen; KIR, killer cell immunoglobulin; OR, odds ratio.
protection or susceptibility to HCV infection. These include
HLA-I, HLA-II, KIR, tapasin and IFN-λ3/4 as described pre-
viously (9, 12, 14). Broadly speaking these represent a cellular
innate immune response (IFN-λ3/4), cytotoxic T-lymphocytic
response (HLA-I and tapasin), T helper responses (HLA-II) and
NK cells (KIR), all of which have been implicated in the out-
come of HCV infection. Our cohort to study SR included 61
resolvers and 296 chronic individuals. Genetic polymorphisms
reaching significance in univariate analysis (Table S1, Support-
ing Information) were entered into a multivariate binary logistic
regression model. The following variables remained indepen-
dently significant: KIR2DL3:HLA-C1C1 (P= 0.006, OR 3.05,
95% CI 1.38–6.74), IFN-λ3/4 rs12979860 CC (P= 0.013, OR
2.55, 95% CI 1.22–5.31), HLA-DRB1*04:01 (P= 0.011, OR
3.70, 95% CI 1.36–10.08) and TapG:HLA-B114D (P= 0.008,
OR 3.22, 95% CI 1.36–7.65) and KIR2DS5 was susceptible
(P= 0.027, OR 0.37, 95% CI 0.16–0.90) (Table 1).
We next examined how these genes interacted in combina-
tion to bring about clearance of HCV. Overall, 6.1% (2/33)
of individuals with no protective factors, 10.8% (12/111) of
individuals with one protective factor, 30.6% (30/98) with
two protective factors and 34.8% (8/23) with three protective
factors resolved infection, P< 0.0001 chi-squared for trend
(Figure 1). To study whether this additional protection was
because of the random association of protective factors acting
independently or a synergistic effect of these genes working
to augment a single immunological pathway, we calculated
P-values and ORs based on the occurrence of the combination
of protective factors in the population, and performed two
types of synergy analysis, the SI and SF (Table 2) (26, 27).
Both synergy tools are designed to account for the expected
increase in protection due to the chance occurrence of the
combination of factors. A SI> 1 indicates an interaction of
either two negative or two positive factors, but a SI of 1 shows
no interaction. Conversely for the SF, synergism of protective
factors produces a SF< 1 and synergism of disadvantageous
factors produces a SF> 1. In both analyses, no statistically
significant synergistic interactions were found, and only a weak
trend towards TapG:HLA-B114D and IFN-λ3/4 rs12979860 CC
interacting synergistically for SR (SF 0.36, P= 0.085, 95%
CI 0.11–1.15; SI 6.95, 95% CI 0.06–752.17) was found.
All other combinations gave null results, with SF> 1 and
Figure 1 The combination of IFN-λ3/4 rs12979860 CC, KIR2DL3:HLA-C1
and TapG:HLA-B114D in determining spontaneous viral clearance.
SI< 1, including the combination of HLA-DRB1*04:01 with
TapG:HLA-B114D and IFN-λ3/4 rs12979860 C despite together
significantly strengthening their OR for bringing about res-
olution, unlike the pairing of KIR2DL3:HLA-C1C1 with
TapG:HLA-B114D or IFN-λ3/4 rs12979860 CC (Tables 1 and
2). Thus for protection against chronic HCV, we propose
that these factors are acting independently in resolving HCV
infection using discrete immunological pathways.
Sustained virological response to pegylated
IFN and ribavirin
To determine if immunological pathways acted discretely or in
concert in treatment-induced responses, and also to determine
the effect of viral genotype, we performed multivariate back-
ward stepwise logistic regression (Table 3) on factors reaching
significance in univariate analysis (Table S2) in patients who
had undergone treatment with available sustained virological
response (SVR) outcome data. To gain additional information
onKIR in our population, we typed 185 patients who had under-
gone treatment with pegylated IFN and ribavirin with a high
resolution KIR typing method (Table S3). This allowed both
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Table 2 Spontaneous resolution (polymorphisms combined)
Univariate analysis Synergy factor Synergy index
Genotype P-value OR (95% CI)
Synergy
factor P-value 95% CI
Synergy
index 95% CI
TapG:HLA-B114D + IFN-λ3/4 rs12979860 CC <0.001 3.84 (2.10–7.03) 0.36 0.085 0.11–1.15 6.95 0.06–752.17
TapG:HLA-B114D +KIR2DL3:HLA-C1C1 0.012 2.37 (1.21–4.67) 2.83 0.194 0.59–13.56 0.97 0.41–2.32
IFN-λ3/4 rs12979860 CC+KIR2DL3:HLA-C1C1 0.070 1.98 (0.95–4.13) 3.32 0.067 0.92–11.95 0.59 0.20–1.70
IFN-λ3/4 rs12979860 CC+HLA-DRB1*04:01 0.004 5.10 (1.69–15.35) 1.92 0.473 0.32–11.44 0.95 0.17–5.30
TapG:HLA-B114D +HLA-DRB1*04:01 0.001 4.51 (1.79–11.36) 1.81 0.612 0.18–17.82 1.00 0.12–8.06
KIR2DL3:HLA-C1C1+HLA-DRB1*04:01 0.999 6.2× 109 (0-.) N/A N/A N/A N/A N/A
KIR2DS3+KIR2DS5 0.240 0.48 (0.14–1.64) 0.29 0.1698 0.049–1.70 0.44 0.06–3.37
CI, conﬁdence intervals; OR, odds ratio.
Table 3 Sustained virological response to pegylated interferon/ribavirin (individual polymorphisms)
Multivariate logistic regression
Genotype SVR n=105 No SVR n=80 P-value OR (95% CI)
All genotypes IFN-λ3/4 rs12979860 CC 42 23 0.265 1.50 (0.73–3.08)
KIR3DS1:HLA-Bw4801 14 3 0.016 5.23 (1.35–20.19)
KIR2DL2/S2:HLA-C1C1 11 19 0.018 0.30 (0.11–0.82)
KIR2DL2 45 47 0.742 0.88 (0.41–1.90)
HCV G1 IFN-λ3/4 rs12979860 CC 15 11 0.043 3.11 (1.04–9.32)
CA01CA01 17 15 0.098 2.51 (0.84–7.49)
HCV G2/3 KIR2DL3:HLA-C1 50 15 0.018 4.90 (1.32–18.25)
CB01 9 9 0.137 0.38 (0.11–1.36)
CI, conﬁdence intervals; OR, odds ratio; SVR, sustained virological response.
gene copy number and haplotype assignment to the cohort (25).
Briefly KIR haplotypes can be categorized as centromeric and
telomeric A and B haplotypes according to the classification of
Cooley et al. (30) As individual KIR genes are in strong link-
age disequilibrium with each other, these haplotypes may be
more strongly associated with disease outcome than individual
genes.We had complete data on 91 patients with HCV genotype
1 infection and 94 with HCV genotype 2 or 3 infection who had
undergone treatment with pegylated IFN/ribavirin dual therapy.
As response to IFN is HCV genotype dependent, we consid-
ered the cohort both as a whole and also divided into those with
genotype 1 vs those with genotype 2/3 infection.
After multivariate logistic regression analysis only
KIR3DS1:HLA-Bw480I (P= 0.016, OR 5.23, 95% CI
1.35–20.19) and KIR2DL2/S2:HLA-C1C1 (P= 0.018, OR
0.30, 95% CI 0.11–0.82) were identified as independent
predictors of outcome in the whole cohort, the first being
protective and the latter leading to treatment failure. In addi-
tion, IFN-λ3/4 rs12979860 CC (P= 0.043, OR 3.11, 95% CI
1.04–9.32) and KIR2DL3:HLA-C1 (P= 0.018, OR 4.90, 95%
CI 1.32–18.25) were protective in HCV in genotype 1 infection
and HCV genotype 2 or 3 infection, respectively (Table 3).
Despite not reaching independent significance, homozygosity
for centromeric motifs of KIR haplotype A (CA01), which
contains KIR2DL3 (P= 0.041, OR 2.74, 95% CI 1.04–7.20)
were associated with treatment response in univariate analysis
in HCV G1 infection and the CB01 haplotype (which contains
KIR2DL2) was closely associated with an absence of SVR in
G2/3 infection (P= 0.051, OR 0.33, 95% CI 0.11–1.01) (Table
S2). We observed no association with any polymorphisms in
HLA-I or HLA-II or tapasin, indicating that innate immune
response are dominant in IFN-related clearance, but that G1
HCV and G2/3 HCV use discrete innate pathways.
Consistent with our data in spontaneous resolvers, the com-
bination of protective factors generated from univariate anal-
ysis for all HCV genotypes, IFN-λ3/4 rs12979860 CC and
KIR3DS1:HLA-Bw480I, did not result in additional benefit (SF
2.60, 95% CI 0.17–39.02; SI 0.39, 95% CI 0.02–7.44, respec-
tively) (Table 4). As a result of susceptibility factors, KIR2DL2
and KIR2DS2 being in linkage disequilibrium at neighboring
loci, with all patients with KIR2DL2 also carrying KIR2DS2,
synergy calculation was precluded for these variables. The
absence of synergy is also present within the HCV genotype 1
cohort, with no significant synergistic interaction being found
between homozygosity for centromeric components of KIR
haplotype A and IFN-λ3/4 rs12979860 CC (SF 0.39, 95% CI
0.04–4.20; SI 7.80, 95% CI 0.24–256.69). Therefore in com-
mon with SR, discrete genetic pathways operate to bring about
IFN induced HCV clearance within an individual. While these
pathways appear to act independently of each other their influ-
ence is strongly linked to HCV genotype.
To ask the question whether there was an association of
HCV genotype with any of these protective factors, we com-
pared the gene frequencies of these polymorphisms within the
270 © 2015 The Authors. Tissue Antigens published by John Wiley & Sons Ltd.
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Table 4 Sustained virological response to pegylated interferon/ribavirin (polymorphisms combined)
Univariate analysis Synergy factor Synergy index
Genotype Polymorphism combination P-value OR (95% CI) Synergy factor P-value 95% CI Synergy index 95% CI
All genotypes IFN-λ3/4 rs12979860
CC+KIR3DS1:HLA-Bw4801
0.181 2.98 (0.60–14.75) 2.60 0.490 0.17–39.02 0.39 0.02–7.44
KIR2DL2/S2:HLA-C1C1+
KIR2DL2
0.014 0.36 (0.16–0.81)
All patients with
KIR2DL2 have KIR
2DS2
All patients with
KIR2DL2 have KIR
2DS2
HCV G1 IFN-λ3/4 rs12979860
CC+CA01CA01
0.009 6.55 (1.61–26.56) 0.39 0.435 0.04–4.20 7.80 0.24–256.69
CI, conﬁdence intervals; OR, odds ratio.
Table 5 Genetic polymorphisms found to be differentially represented
between HCV G1 and HCV G2/3 infected patients
HCV G1
Actual count
(expected
count)
HCV G23
Actual count
(expected
count)
Univariate
analysis
(P-value) OR (95% CI)
KIR2DS1 36 (43.9) 55 (47.1) 0.033 1.80 (1.05–3.10)
KIR2DS1:C2 17 (24.6) 33 (26.2) 0.022 2.16 (1.12–4.18)
KIR2DS5 25 (33.4) 44 (36.1) 0.020 2.00 (1.12–3.58)
KIR3DS1 33 (40.6) 51 (43.6) 0.039 1.78 (1.03–3.09)
CI, conﬁdence intervals; OR, odds ratio.
G1 and G2/3 groups. We found that KIR2DS1, KIR2DS5 and
KIR3DS1 (all components of KIR B telomeric haplotypes)
were relatively over-represented in the G2/3 group suggesting
that these polymorphisms may lead to susceptibility to chronic
infection with G2/3 HCV (Table 5). The correlation between
fixed telomeric haplotype B KIR alleles and HCVG2/3 may
be explained by the association of motifs of haplotype B with
failure to reach both spontaneous and treatment-induced clear-
ance, leading to a population bias, despite analysis of B hap-
lotypes directly not being significantly associated with HCV
genotype; CB01 P= 0.365 (OR 0.74, 95% CI 0.39–1.41) and
TB01 P= 0.098 (OR 1.64, 95% CI 0.91–2.95).
Principal component analysis
To test conclusions from our synergy analysis, we assessed
whether patients with similar binary outcomes for KIR,
IFN-λ3/4, HLA alleles and the tapasin G/C polymorphism
would cluster according to outcome using PCA. Prior to PCA
analyses SNPs were removed that were not measured for the
majority of patients to exclude patients with missing values.
In addition, KIRs with multiple copy numbers were excluded
to retain the binary data required for PCA, leaving a total
of 192 patients and 102 SNPs. While individuals could be
seen to cluster into four groups, overlaying outcome data for
both SR and SVR could not explain this clustering, providing
additional evidence of an absence of anything further than
an additive benefit between SNPs from different pathways to
resolution (Figure 2). Patients also did not cluster according
to previously identified SNPs thought to be key to resolution
including IFN-λ3/4 rs12979860 CC, KIR2DL3:C1C1 and
TapG:HLA-B114D (Figure 3) suggesting that presence of one
isolated polymorphism is not enough to significantly define
the rest of a patient’s genome. Clusters were only found to be
linked toKIR haplotypes and some of their definingKIR alleles,
KIR2DL2, KIR2DS3, KIR2DS5 and KIR3DS1:HLA-Bw480I.
Disease progression
In order to investigate whether similar polymorphisms were
associated with disease progression, we analyzed the frequency
of IFN-λ3/4 rs12979860 CC, TapG:HLA-B114D, KIR and HLA
polymorphisms known to be important for HCV resolution
in patients with chronic hepatitis C who developed cirrhosis
compared with those who did not. An outcome was available
for 286 patients, of which 78 were cirrhotic. Cirrhosis was
defined histologically in 56 patients (71.8%). In those who
did not have a biopsy, cirrhosis was defined using a fibroscan
score of greater than 12 kPa in three patients (3.8%) and an
AST to platelet ratio index (APRI) score of greater than one
in the remaining 19 (24.4%). Investigating all the SNPs asso-
ciated with resolution of HCV using univariate analysis, we
found only the centromeric KIR haplotype B to be associ-
ated with cirrhosis free survival (P= 0.034, OR 2.25, 95% CI
1.06–4.77) (Table 6). On multivariate analysis of significant
polymorphisms, the inhibitory KIR2DL2 allele, a component
of centromeric KIR B haplotypes, was protective (P= 0.029,
OR 2.94, 95% CI 1.12–7.73). Thus, factors determining dis-
ease progression are distinct from those determining both spon-
taneous and treatment-induced resolution. Interestingly of the
eight cirrhotic patients who developed HCC and had KIR geno-
typing available, none carried a centromeric B haplotype, but
this was not statistically significant (P> 0.1).
Discussion
We have studied a well characterized homogenous UK popu-
lation, in which a number of genetic determinants known to
influence the outcome of HCV infection have been previously
identified. On aworldwide basis, different populations have dif-
ferent genetic factors that influence outcome of HCV infection.
© 2015 The Authors. Tissue Antigens published by John Wiley & Sons Ltd. 271
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(A) (B)
Figure 2 Overlay of hepatitis C outcome data on principal component analysis plots. (A) Spontaneous resolution. Red circles: spontaneous resolution;
black circles: chronic infection. (B) Treatment-induced resolution. Red circles: sustained virological response; black circles: no sustained virological
response; gray circles: lost to follow-up or not treated.
This cohort has provided us with an opportunity to investigate
how different protective factors interact in a single cohort at
an immunological level. We have studied different outcomes of
HCV infection using different statistical tools in order to ensure
that our primary finding, that these pathways do not appear to
interact, is robust.
Although patients achieve spontaneous clearance through
IFN-λ3/4, TapG:HLA-B114D, KIR2DL3:HLA-C1 or
HLA-class II (HLA-DRB1*04:01), these pathways operate
independently. Thus, although having more than one protective
SNP appears beneficial statistically (Figure 1), these interac-
tions are additive, i.e. because of the random occurrence of two
protective genes, rather than synergistic, in which the interac-
tion of two or more genes would produce a combined effect
greater than the sum of their separate effects on HCV resolu-
tion. We used stringent criteria to define protective interactions,
including an improvement in the OR of resolving HCV with
the tested gene combinations, two types of synergy analysis
and PCA, which is designed to assess the covariance structure
of a data set composed of binary outcomes. Overall, none of the
individually protective or susceptible genes met these criteria in
combination. These data imply that the genetic pathways that
lead to resolution of HCV infection are multiple and relatively
discrete. Previous work has shown that combining KIR cen-
tromeric A/A genotypes with IFN-λ3/4 improves its positive
predictive value in determining treatment outcome (31). How-
ever, this is at the expense of a lower sensitivity, and the authors
did not test whether this interaction was synergistic or not. Con-
versely, susceptibility factors appear to increase susceptibility.
This was found in an Irish cohort, but not a larger international
study (20, 21). Similarly, considering viral genotype and the
response to IFN-based therapy, IFN-λ3/4 and centromeric
A KIR haplotypes are important for treatment-induced res-
olution of patients infected with HCV G1, whereas the
KIR2DL3 and HLA-class I combination, but not IFN-λ3/4,
plays a dominant role in resolving HCV G2 and G3 infection.
Thus, subtly different pathways operate for different viral
genotypes.
While our data infer that pathways to resolution and
non-resolution act independently of each other, it is also likely
that diversity within the HCV host immune response seen
between discrete populations has a significant effect. Hetero-
geneity at a population level has continued to contribute to
substantial variation seen between studies in HCV resolution.
For example for KIR in the UK population, KIR2DL3:HLA-C1
is protective (8), but this is not found in the cohort of Irish
women infected from a single source (20). In a Swiss cohort,
the rs8099917 IFN-λ3/4 minor allele failed to show any asso-
ciation with treatment in patients infected with HCV G2/3, but
this was not the case when later repeated in a cohort of over
1000 Australians, also of Caucasian ethnicity (6, 32). In terms
of HLA-class I, HLA-B*08 has been linked to viral persistence
in the Irish HCV and an US cohort, but could not be replicated
in an East German population (33–35). HLA-DQB1*0301
was found to be protective in largely Caucasian cohorts in
France, the UK and Italy, but only in black populations in the
United States, showing that geographical location, and hence
the infecting HCV virion may be a determinant of response
rather than ethnicity alone (18, 36–38). Finally, the protective
influence of tapasin occurs in European Caucasians but not US
Caucasians (9).
Our study has shown an important role of KIR haplotypes in
HCV resolution, with the assay used being able to assign KIR
haplotypes as opposed to simply gene content. These diverse
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Figure 3 Overlay of single nuclear polymorphisms known to be important for hepatitis C clearance on principal component analysis plots. (A) IFN-λ3/4
rs12979860 CC, (B) KIR2DL3:HLAC1C1 and (C) TapG:HLA-B114D. Red circles: polymorphism present; black circles: polymorphism absent.
Table 6 Genetic polymorphisms in disease progression
Univariate analysis Multivariate logistic regression
Genotype Cirrhosis n=78 No cirrhosis n=208 P-value OR (95% CI) P-value OR (95% CI)
IFN-λ3/4 rs12979860 CC 36 74 0.174 0.69 (0.40–1.18) 0.776 0.86 (0.30–2.48)
TapG:HLA-B114D 39 102 0.597 1.17 (0.66–2.07) 0.637 1.29 (0.45–3.69)
KIR2DL3:HLA-C1 45 131 0.393 1.34 (0.69–2.61) 0.831 0.85 (0.19–3.77)
KIR2DL3:HLA-C1C1 23 47 0.315 0.73 (0.40–1.34) 0.399 0.63 (0.21–1.85)
KIR3DS1:HLA-Bw4801 7 18 0.884 0.93 (0.37–2.34) 0.336 0.44 (0.08–2.36)
KIR2DL2 32 114 0.071 1.65 (0.96–2.86) 0.029 2.94 (1.12–7.73)
KIR2DS2:HLA-C1C1 11 31 0.695 1.16 (0.55–2.46) 0.772 0.76 (0.12–4.85)
KIR2DS3 15 54 0.106 1.71 (0.89–3.29) 0.928 1.13 (0.88–14.45)
KIR2DS5 25 60 0.981 0.99 (0.56–1.77) 0.332 1.72 (0.58–5.15)
CA01CA01 33 72 0.108 0.62 (0.34–1.11) 0.792 1.48 (0.81–27.0)
CB01 10 53 0.034 2.25 (1.06–4.77) 0.553 1.61 (0.33–7.76)
HLA-DRB1*04:01 2 10 0.401 1.96 (0.41–9.47) 0.182 4.39 (0.50–38.62)
CI, conﬁdence intervals; OR, odds ratio.
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haplotypes have been broadly split into A and B groupings, with
the former having one or no functional activating KIR and the
latter having several activating KIR. The B group of haplotypes
contains genes associated with chronic HCV infection and poor
treatment response, including KIR2DL2 and KIR2DS2, but
has a minor protective role against end stage manifestations
including cirrhosis and HCC, possibly through the activation of
NK cells leading to stellate cell apoptosis in the case of fibrosis
(39–42). Activating KIR, components of the KIRB haplotypes,
have been previously shown to have a beneficial effect against
HCC development (42).We found no other association between
genes which influence viral clearance and disease progression.
This work advances our knowledge of how immune path-
ways, influenced by key genetic polymorphisms, act indepen-
dently of each other to bring about both spontaneous and
treatment-induced viral clearance in a single Caucasian popula-
tion. We also show that population diversity within the immune
response is likely to account for discordant results between
studies, and that while consideration of large populations may
be important for discovering widespread protective factors,
the study of discrete populations is likely to be important for
defining additional protective alleles. Future designers of HCV
immunogenetic studies will need to consider stratifying patients
according to major characteristics of populations including eth-
nicity, and be aware that findings are likely to be population
discrete. Our results highlight the effect of HCV genotype
on dictating whether recognized protective SNPs will be able
to influence viral clearance as an interesting topic for further
investigation. From a clinical perspective, our data implies the
utilization of immunogenetics to guide IFN-based therapy will
require knowledge of the HCV genotype and a personalized
approach and that there is no ‘super’ combination of SNPs
that can be used to strongly enhance our current predictive
models.
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